Impact of a Multi-Strain L. Crispatus-Based Vaginal Synbiotic on the Vaginal Microbiome: A Randomized Placebo-Controlled Trial

Authors

Jacques Ravel
Sheri Simmons
Eleni Greenwood Jaswa
Sara Gottfried, Thomas Jefferson UniversityFollow
Miriam Greene
Susan Kellogg-Spadt
Dirk Gevers
Diane M. Harper

Document Type

Article

Publication Date

8-9-2025

Comments

This article is the author's final published version in NPJ Biofilms Microbiomes, Volume 11, Issue 1, August 2025, Article Number 158.

The published version is available at https://doi.org/10.1038/s41522-025-00788-6. Copyright © The Author(s).

Abstract

A clinical trial of a multi-strain vaginal synbiotic (NCT05659745, registered 12/19/2022 at clinicaltrials.gov) led to an optimal vaginal microbiome dominated by L. crispatus (CST I). The synbiotic led to a significant increase in L. crispatus compared to placebo (p <  0.05), and conversion to CST I was significantly higher with the vaginal synbiotic than with placebo (90 vs 11%; p <  0.002). Mechanistically, the synbiotic reduced Gardnerella vaginalis and Candida, clinically important microbes.

Recommended Citation

Ravel, Jacques; Simmons, Sheri; Jaswa, Eleni Greenwood; Gottfried, Sara; Greene, Miriam; Kellogg-Spadt, Susan; Gevers, Dirk; and Harper, Diane M., "Impact of a Multi-Strain L. Crispatus-Based Vaginal Synbiotic on the Vaginal Microbiome: A Randomized Placebo-Controlled Trial" (2025). Institute of Emerging Health Professions Faculty Papers. Paper 31.
https://jdc.jefferson.edu/iehpfp/31

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Language

English